Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-16

Study Completion Date

2018-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase Ib multi-center, open-label study: escalation part followed by expansion part. The primary purpose of the Phase Ib CBCL201X2102C study is to characterize the safety and tolerability of BCL201 combined with idelalisib in patients with FL and MCL.

Approximately 65 patients are to be enrolled.

The primary endpoint for the Phase Ib is frequency, severity and seriousness of AEs, lab abnormalities and other safety parameters such as ECG changes. An adaptive Bayesian logistic regression model (BLRM) will guide the dose escalation to determine the MTD/RDE in phase Ib. In addition Bayesian regression models will be used to estimate the dose-exposure relationships for both BCL201 and idelalisib in order to guide the escalation steps. A Bayesian method for the expansion part will be used for the primary activity objective.

The study data will be analyzed and reported based on all patients' data of the escalation and expansion part.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT01088048

Indolent Non-Hodgkin's Lymphoma Chronic Lymphocytic Leukemia Mantle Cell Lymphoma

COMPLETED PHASE1

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

NCT02242045

Chronic Lymphocytic Leukemia Indolent Non-Hodgkin Lymphoma Follicular Lymphoma +3 more

COMPLETED PHASE1

Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

NCT01582776

Follicular Lymphoma Patients (Phase IB) Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)

COMPLETED PHASE1/PHASE2

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

NCT03478514

Mantle Cell Lymphoma B Cell Lymphoma

ACTIVE_NOT_RECRUITING PHASE2

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

NCT00445341

Lymphoma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Follicular Lymphoma, Mantle Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Follicular lymphoma (FL)

Group Type EXPERIMENTAL

BCL201

Intervention Type DRUG

Idelalisib

Intervention Type DRUG

Mantle cell lymphoma (MCL)

Group Type EXPERIMENTAL

BCL201

Intervention Type DRUG

Idelalisib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BCL201

Intervention Type DRUG

Idelalisib

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

S55746 Idela

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of FL or MCL according to WHO 2008
* Relapsed or refractory with at least one (FL) or two (MCL), but not more than four, prior lines of antineoplastic regimens.
* Either FDG-avid on FDG-PET or measurable disease by CT on cross sectional imaging: \> 1.5 cm for nodal lesion, \> 1.0 cm for extra nodal lesion.
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

Exclusion Criteria

* For dose escalation part: Patients with MCL at high risk for tumor lysis syndrome
* Prior treatment with PI3Kδ or Bcl-2 inhibitors.
* Any other malignant disease
* History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis
* Inadequate organ function
* Concomitant treatment with:
* Strong CYP3A4/5 inducers or inhibitors
* Sensitive CYP3A4/5 substrates or CYP3A4/5 substrates with narrow therapeutic index (NTI)
* Sensitive CYP2D6 substrates or CYP2D6 substrates with NTI
* Selected dual substrates of CYP3A4/5 and CYP2C8
* Selected dual substrates of CYP3A4/5 and CYP2D6
* Selected dual substrates of OATP and CYP450
* Selected dual substrates of CYP3A4/5 and P-gp
* NTI P-gp substrates
* QT prolonging drugs with a known risk to induce TdP
* Proton pump inhibitors
* Treatment by warfarin or equivalent vitamin K antagonists.
* Other investigational therapies
* Herbal preparations/ medications
* Grapefruit, Seville oranges or products containing either juice

Other protocol-defined inclusion/exclusion may apply.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No